Literature DB >> 5391106

Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy.

B Alexanderson, D A Evans, F Sjöqvist.   

Abstract

Nineteen identical (monozygotic) and 20 fraternal (dizygotic) sets of twins between 45 and 51 years of age were given nortriptyline orally in doses of 0.2 mg./kg. body weight three times daily for eight days. The steady-state plasma concentrations of nortriptyline were calculated from the mean of the determinations for days 6, 7, and 8. Identical twins, not treated with other drugs, achieved similar steady-state plasma concentrations of nortriptyline in contrast to fraternal twins who were not given other drugs. The intrapair similarity in steady-state plasma concentrations was not found in identical twins simultaneously treated with various drugs during the experiment. Identical and fraternal twins treated with drugs containing barbiturates had considerably lower steady-state plasma concentrations of nortriptyline compared with untreated twins.It is concluded that most of the variability in nor-triptyline steady-state plasma concentration between persons who have not received drugs is genetically determined. Exposure to other drugs also influences the steady-state plasma concentration of nortriptyline, which in a given patient may therefore be determined by a resultant of genetic and environmental factors.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5391106      PMCID: PMC1630282          DOI: 10.1136/bmj.4.5686.764

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  14 in total

1.  [QUANTITATIVE METHODS FOR STUDYING THE METABOLISM OF TOFRANIL].

Authors:  B HERRMANN
Journal:  Helv Physiol Pharmacol Acta       Date:  1963

2.  THE METABOLISM OF NORTRIPTYLINE-N-METHYL-14C IN RATS.

Authors:  R E MCMAHON; F J MARSHALL; H W CULP; W M MILLER
Journal:  Biochem Pharmacol       Date:  1963-10       Impact factor: 5.858

3.  Aspects of the clinical chemistry of desmethylimipramine in man.

Authors:  C M YATES; A TODRICK; A C TAIT
Journal:  J Pharm Pharmacol       Date:  1963-07       Impact factor: 3.765

4.  Rate of accumulation and plateau plasma concentration of drugs after chronic medication.

Authors:  J M van Rossum; A H Tomey
Journal:  J Pharm Pharmacol       Date:  1968-05       Impact factor: 3.765

5.  Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.

Authors:  A J Levi; S Sherlock; D Walker
Journal:  Lancet       Date:  1968-06-15       Impact factor: 79.321

6.  Genetic control of drug levels in man: antipyrine.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-07-05       Impact factor: 47.728

7.  Some pharmacological consequences of species variation in rates of metabolism.

Authors:  B B Brodie; W D Reid
Journal:  Fed Proc       Date:  1967 Jul-Aug

8.  Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds.

Authors:  W Hammer; F Sjöqvist
Journal:  Life Sci       Date:  1967-09-01       Impact factor: 5.037

9.  [Activity of expired carbon dioxide, CNS and other organs after the administration of C14-labelled N-(gamma-dimethyl-aminopropyl)-iminodibenzyl (psychopharmacological drug Tofranil) to rats and dogs].

Authors:  K BERNHARD; H BEER
Journal:  Helv Physiol Pharmacol Acta       Date:  1962

10.  Enzyme stimulation and inhibition in the metabolism of drugs.

Authors:  J J Burns; A H Conney
Journal:  Proc R Soc Med       Date:  1965-11
View more
  83 in total

1.  The relationship between nortriptyline plasms levels and clinical effects.

Authors:  P Kragh-Sorensen
Journal:  Proc R Soc Med       Date:  1975-02

Review 2.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

3.  Population characteristics of biological systems influenced by multicomponent random and uniform variation.

Authors:  G M Kochak
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

4.  The "top 50": a perspective on the BMJ drawn from the Science Citation Index.

Authors:  B Dixon
Journal:  BMJ       Date:  1990-10-03

5.  The assessment of potential drug interactions with a new tricyclic antidepressant drug.

Authors:  R H Briant; C F George
Journal:  Br J Clin Pharmacol       Date:  1974-04       Impact factor: 4.335

6.  The effect of fluphenazine on steady state plasma levels of nortriptyline.

Authors:  I H Stevenson; A A Schiff
Journal:  Br J Clin Pharmacol       Date:  1974-08       Impact factor: 4.335

7.  Plasma concentrations of tricyclic antidepressive drugs.

Authors:  M Lader
Journal:  Br J Clin Pharmacol       Date:  1974-08       Impact factor: 4.335

Review 8.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 9.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

10.  Inhibition of platelet uptake of serotonin in plasma from patients treated with clomipramine and amitriptyline.

Authors:  O Lingjaerde
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.